1571-88-6

Basic information

• Product Name: 1H-Benzimidazole, 2-(3-chlorophenyl)-5-nitro-
• CAS NO: 1571-88-6
• Molecular Formula: C13H8ClN3O2
• Molecular Weight: 273.678
• Mol File: 1571-88-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1H-Benzimidazole, 2-(3-chlorophenyl)-5-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole, 2-(3-chlorophenyl)-5-nitro-(1571-88-6)
• EPA Substance Registry System: 1H-Benzimidazole, 2-(3-chlorophenyl)-5-nitro-(1571-88-6)

Safety Data

• Hazardous Substances Data: 1571-88-6(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazole, 2-(3-chlorophenyl)-5-nitro- is a chemical compound that belongs to the benzimidazole class. It is characterized by a benzene ring fused to an imidazole ring with a 2-(3-chlorophenyl)-5-nitro- substitution pattern. 1H-Benzimidazole, 2-(3-chlorophenyl)-5-nitro- has a nitro group at the 5th position and a chlorophenyl group at the 3rd position of the benzimidazole ring. It is commonly used in medicinal chemistry as a building block for the synthesis of various pharmaceutical compounds, including antiparasitic, antimicrobial, and antiviral agents. The 2-(3-chlorophenyl)-5-nitro- substitution pattern is known to impart specific biological activities to the molecules it is incorporated into, making this compound an important tool in drug discovery and development.

Upstream product

• 587-04-2 m-Chlorobenzaldehyde 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 535-80-8 3-chlorobenzoate 
• 4152-90-3 m-chlorobenzylamine 

Downstream Products

• 1572-03-8 2-(3-chlorophenyl)-1H-benzo[d]imidazol-5-amine 
• 1593834-62-8 N-(2-(3-chlorophenyl)-1H-benzo[d]imidazol-6-yl)quinolin-4-amine 

Relevant articles and documents

COMPOUNDS FOR TREATING TUBERCULOSIS

The invention concerns a compound of formula (Ia) or (Ib) wherein R1 is hydrogen or a methyl group; R2 is an unsubstituted or substituted alkyl group; R3 is an aryl group or a heteroaryl group, optionally substituted by on

Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7)

Here, we report the discovery of a new class of NPBWR1 antagonists identified from a fragment-based screen. Compound 1 (cAMP IC50 = 250 μM; LE = 0.29) emerged as an initial hit. Further optimization of 1 by SAR-by-catalogue and chemical modification produced 21a (cAMP IC50 = 30 nM; LE = 0.39) with a 6700-fold increase in potency from fragment 1. Somewhat surprisingly, Schild analysis of compound 21a suggested that in vitro inhibition of NPW-mediated effects on upon cAMP accumulation were saturable, and that compound 21a dose-dependently increased [125I]-hNPW23 dissociation rate constants from NPBWR1 in kinetic binding studies. Collectively, these data are inconsistent with a classic surmountable, orthosteric mechanism of inhibition. The benzimidazole inhibitors reported herein may therefore represent a mechanistically differentiated class of compounds with which to form a better appreciation of the pharmacology and physiological roles of this central neuropeptide system.

Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2

Both c-Met and VEGFR-2 are important targets for the treatment of cancers. In this study, a series of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinazolin-4- amine derivatives were designed and identified as dual c-Met and VEGFR-2 inhibitors. Among these compounds bearing quinazoline and benzimidazole fragments, compound 7j exhibited the most potent inhibitory activity against c-Met and VEGFR-2 with IC50 of 0.05 μM and 0.02 μM, respectively. It also showed the highest anticancer activity against the tested cancer cell lines with IC50 of 1.5 μM against MCF-7 and 8.7 μM against Hep-G2. Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the ATP-binding site of c-Met and VEGFR-2, which demonstrates that compound 7j is a potential agent for cancer therapy deserving further researching.